Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) released a new CEO Corner segment on April 7, 2026 featuring CEO Walter Klemp discussing Annamycin’s non-cardiotoxic safety profile. The company says Annamycin avoided cardiac damage in preclinical and clinical studies, which could broaden options for relapsed/refractory AML and advanced solid tumor patients.
Mr. Klemp noted potential benefits for physicians, and favorable regulatory and commercial implications as the company advances the MIRACLE Study.
Positive
- None.
Negative
- None.
News Market Reaction – MBRX
On the day this news was published, MBRX gained 3.88%, reflecting a moderate positive market reaction. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $486K to the company's valuation, bringing the market cap to $13.02M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Peers show mixed moves: LPTX up 238.84%, MBIO up 0.8%, while INTS and SNGX are down 5.31% and 1.72%. With MBRX flat on the day, trading appears more stock-specific than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Trial enrollment milestone | Positive | +1.9% | Reported 45th subject enrollment and interim MIRACLE data unblinding preparations. |
| Mar 19 | Earnings and trial update | Neutral | -1.0% | Full-year 2025 results and reiterated MIRACLE interim unblinding timeline and CRc data. |
| Mar 17 | Conference participation | Positive | +5.4% | Announcement of participation in the 38th Annual ROTH investor conference. |
| Mar 11 | CEO Corner update | Positive | +3.0% | New CEO Corner segment on MIRACLE study design and enrollment progress. |
| Feb 19 | Warrant exercise financing | Negative | -44.3% | Announced warrant exercises and issuance of new warrants for $8.3M gross proceeds. |
Recent operational and CEO communication updates have often coincided with modest positive price moves, while financing-related actions drew a sharply negative reaction.
Over the last few months, Moleculin has focused investors on the pivotal MIRACLE trial for Annamycin. Enrollment milestones and CEO Corner segments on the study and strategy (e.g., news on Mar 11 and Mar 23) coincided with modest gains, while a conference appearance on Mar 17 also saw a positive move. In contrast, the warrant-related financing news on Feb 19 produced a steep one-day decline. Today’s CEO Corner segment on Annamycin’s non-cardiotoxic profile reinforces the clinical differentiation theme highlighted throughout these prior updates.
Regulatory & Risk Context
An effective S-3 shelf has been filed to register up to 6,367,956 warrant-related resale shares. Full cash exercise at the initial $2.3976 exercise price would result in gross proceeds of $15.3 million, but would also add a significant number of shares relative to current outstanding levels.
Market Pulse Summary
This announcement highlights Annamycin’s non-cardiotoxic safety profile, contrasting it with traditional anthracyclines like doxorubicin and positioning it for relapsed or refractory AML and advanced solid tumors. It complements prior disclosures about the pivotal MIRACLE trial and emphasizes potential regulatory and commercial advantages of a differentiated safety profile. Investors may watch for upcoming interim unblinding milestones, the impact of registered warrant-related resale shares, and how future data further corroborate the non-cardiotoxicity narrative.
Key Terms
cardiotoxicity medical
anthracyclines medical
doxorubicin medical
acute myeloid leukemia medical
AML medical
solid tumors medical
oncology medical
AI-generated analysis. Not financial advice.
Access the Moleculin CEO Corner here
HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.
In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac damage, and has demonstrated this advantage across preclinical and clinical studies. This non-cardiotoxic profile could expand treatment options for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced solid tumors, particularly those previously treated with anthracyclines or with existing cardiac risk factors. Mr. Klemp also notes the potential benefits for physicians in enabling more flexible treatment strategies, as well as the favorable regulatory and commercial implications of a differentiated safety profile. As the Company advances its MIRACLE Study, he underscores that Annamycin’s unique design may position it as a promising new option in oncology, with the potential to reshape the use of anthracyclines in modern cancer care.
Access the CEO Corner on the Company’s website here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding the continued recruitment, treatment, and receipt of the unblinded data for the first 45 subjects of the MIRACLE clinical trial as described. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
